UAB experts investigate the effectiveness of P4 phantom on neoadjuvant chemotherapy treatments in borderline-resectable pancreatic cancer
Borderline-resectable pancreatic cancer (BRPC) accounts for nearly 20% of all pancreatic cancer cases diagnosed in the U.S. These tumors are often attached to nearby arteries or veins, making surgery difficult and risky. However, chemotherapy can shrink tumors, sometimes making surgery a viable option. Currently, two main chemotherapy regimens are used for BRPC, but there is no clear evidence favoring one over the other.
El-Rayes Named Director for the Division of Hematology and Oncology
The DOM is delighted that Bassel El-Rayes, M.D., will serve as the next Director of the Division of Hematology and Oncology. He will also serve as the deputy director for the The O’Neal Comprehensive Cancer Center at UAB - effective March 1, 2022. Dr. El-Rayes is the John Kauffman Family Endowed Professor for Pancreatic Cancer Research at Emory University School of Medicine where he serves as Professor of Hematology and Medical Oncology and Vice Chair for Clinical Research in the Department of Hematology and Medical Oncology. He also serves as Director of Clinical and Translational Gastrointestinal Malignancies Program and Associate Cancer Center Director for Clinical Research in Emory’s Winship Cancer Institute.